Antiviral and antioxidant activity of a hydroalcoholic extract from Humulus lupulus L.

A hydroalcoholic extract from female inflorescences of Humulus lupulus L. (HOP extract) was evaluated for its anti-influenza activity. The ability of the extract to interfere with different phases of viral replication was assessed, as well as its effect on the intracellular redox state, being unbalanced versus the oxidative state in infected cells. The radical scavenging power, inhibition of lipoperoxidation, and ferric reducing activity were assayed as antioxidant mechanisms. A phytochemical characterization of the extract was also performed. We found that HOP extract significantly inhibited replication of various viral strains, at different time from infection. Viral replication was partly inhibited when virus was incubated with extract before infection, suggesting a direct effect on the virions. Since HOP extract was able to restore the reducing conditions of infected cells, by increasing glutathione content, its antiviral activity might be also due to an interference with redox-sensitive pathways required for viral replication. Accordingly, the extract exerted radical scavenging and reducing effects and inhibited lipoperoxidation and the tBOOH-induced cytotoxicity. At phytochemical analysis, different phenolics were identified, which altogether might contribute to HOP antiviral effect. In conclusion, our results highlighted anti-influenza and antioxidant properties of HOP extract, which encourage further in vivo studies to evaluate its possible application

Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus

In the first part of this overview, we described the life cycle of the influenza virus and the pharmacological action of the currently available drugs. This second part provides an overview of the molecular mechanisms and targets of still-experimental drugs for the treatment and management of influenza.Briefly, we can distinguish between compounds with anti-influenza activity that target influenza virus proteins or genes, and molecules that target host components that are essential for viral replication and propagation. These latter compounds have been developed quite recently. Among the first group, we will focus especially on hemagglutinin, M2 channel and neuraminidase inhibitors. The second group of compounds may pave the way for personalized treatment and influenza management. Combination therapies are also discussed.In recent decades, few antiviral molecules against influenza virus infections have been available; this has conditioned their use during human and animal outbreaks. Indeed, during seasonal and pandemic outbreaks, antiviral drugs have usually been administered in monotherapy and, sometimes, in an uncontrolled manner to farm animals. This has led to the emergence of viral strains displaying resistance, especially to compounds of the amantadane family. For this reason, it is particularly important to develop new antiviral drugs against influenza viruses. Indeed, although vaccination is the most powerful means of mitigating the effects of influenza epidemics, antiviral drugs can be very useful, particularly in delaying the spread of new pandemic viruses, thereby enabling manufacturers to prepare large quantities of pandemic vaccine. In addition, antiviral drugs are particularly valuable in complicated cases of influenza, especially in hospitalized patients.To write this overview, we mined various databases, including Embase, PubChem, DrugBank and Chemical Abstracts Service, and patent repositories

Advances in the development of entry inhibitors for sialic-acid-targeting viruses

Over the past decades, several antiviral drugs have been developed to treat a range of infections. Yet the number of treatable viral infections is still limited, and resistance to current drug regimens is an ever-growing problem. Therefore, additional strategies are needed to provide a rapid cure for infected individuals. An interesting target for antiviral drugs is the process of viral attachment and entry into the cell. Although most viruses use distinct host receptors for attachment to the target cell, some viruses share receptors, of which sialic acids are a common example. This review aims to give an update on entry inhibitors for a range of sialic-acidtargeting viruses and provides insight into the prospects for those with broad-spectrum potential

In Vitro Analysis of the Anti-influenza Virus Activity of Pomegranate Products and Fulvic Acid

In traditional cuban medicine, pomegranate fruits have been used to treat acidosis, dysentery, microbial infections, diarrhoea, helminthiasis; haemorrhage and respiratory pathologies [Vuorela et al., 2003; Roig, 1974; Jimenez et al., 1979; Seoane, 1984].Pomegranates contain high levels of Polyphenolic compounds, which are largely responsible for the fruit’s antioxidant properties. A number of studies have demonstrated that polyphenolic complexes derived from other plants have antiviral effects, suggesting that antiviral activity may also reside in the polyphenol (PP) fraction of pomegranates. The decay of organic matter generates an extremely heterogeneous mixture of organic molecules referred to as humic substances. They are sub-classified on the basis of solubility characteristics. The Fulvic Acid (FA) fraction of humic substances includes a variety of low molecular acidic molecules that are soluble in water under all pH conditions. Antiviral activity of fulvic acid containing Secomet V against poxviruses and SARS has been demonstrated [Kotwal et al., 2006]. The current study was undertaken to evaluate the direct anti-influenza virus activity of pomegranate constituents present in Pomegranate Extracts: Pomegranate Juice (PJ) Pomegranate Liquid Extract (POMxl), Pomegranate Polyphenol enriched Powder Extract (POMxp) and Fulvic Acid (FA). Both Pomegranate Extracts and Fulvic Acid had anti-influenza activity. With regard to Pomegranate Extracts, all of the extracts had rapid antiviral activity when combined with influenza virus. The acidity of PJ and POMxl solutions contributed to anti-influenza activity, but this was not a factor with POMxp. Studies using POMxp showed that brief treatment at room temperature with \u3e 200 ìg/ml PPs substantially reduced the infectivity of H1N1, H3N2, and H5N1 influenza viruses. Generally, the loss of infectivity was accompanied by loss of hemagglutinating activity. Electron microscopic examination of influenza particles neutralized by PP treatment identified a coating of amorphous material and some damage to virion integrity. Reassortant H5N1 viruses derived from avian isolates were less affected by PP treatment, indicating that PP susceptibility is modulated by small changes in surface glycoproteins. Our analysis supports the development of pomegranate-derived PPs as natural, rapidly active, broad-spectrum anti-influenza agents. Our finding demonstrates rapid anti-influenza virus activity in Pomegranate PPs and the Fulvic Acid

Conjugating drug candidates to polymeric chains does not necessarily enhance anti-influenza activity

Using the plaque reduction assay, relatively simple bicyclic quinone molecules, as well as multiple copies thereof covalently attached to a long polyglutamate-based polymeric chain, were examined as new inhibitors of various naturally occurring strains of influenza A virus. The polymer-conjugated inhibitors were found to have a far greater potency (for some as high as two orders of magnitude when a long spacer arm was employed) than their corresponding parent molecules against the human Wuhan influenza strain. However, such polymeric inhibitors failed to exhibit higher potency compared with their small molecule predecessors against the human Puerto Rico and avian turkey influenza strains. These observations, further explored by means of molecular modeling, reveal the previously unrecognized unpredictability of the benefits of multivalency, possibly because of poor accessibility of the viral targets to polymeric agentsNational Institutes of Health (U.S.) (Grant U01-AI074443

Identification Of Potential Neuraminidase Inhibitors Using Ensemble-Based Virtual Screening

To date, influenza A virus cause a serious impact in human health. It has emerged as a worldwide pandemic threat in the 21st century where large human populations were affected annually. At present, Oseltamivir (Tamiflu) and Zanamivir (Relenza) have become important treatments for influenza infectious disease. Unfortunately, the resistance of influenza viruses to these drugs has been reported recently. So, it is important to discover new anti-influenza inhibitors to overcome the on-going and potential influenza outbreak. This project is about the discovery of the potential inhibitor for influenza infectious disease via ensemble-based virtual screening. As a receptor destroying enzyme, neuraminidase has been widely used as a drug target for drug discovery. Thus, this study was focused on Neuraminidase subtype-1. Variation of neuraminidase conformations from Protein Data Bank (PDB) and molecular dynamics (MD) simulation structures were used in this study. With the aid of computational resource, ensemble-based virtual screening was performed. Neuraminidase was screened against the National Cancer Institute (NCI) Database and the Natural Product Discovery System (NADI) Database to discover the potential compounds as the neuraminidase inhibitors. From docking results, 20 compounds from NCI Database were selected. For NADI Database, there were 40 compounds have been selected and they were clustered into 7 plants. All these compounds (NCI and NADI) were able to bind to all 13 ensemble structures. This has exhibited the probable anti-neuraminidase activity. These compounds were then subjected to inhibitory activity evaluation via MUNANA assay

N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction

The influenza virus hemagglutinin (HA) is an attractive target for antiviral therapy due to its essential role in mediating virus entry into the host cell. We here report the identification of a class of N-benzyl- 4,4,-disubstituted piperidines as influenza A virus fusion inhibitors with specific activity against the H1N1 subtype. Using the highly efficient one-step Ugi four-component reaction, diverse library of piperidine-based analogues was synthesized and evaluated to explore the structure-activity relation- ships (SAR). Mechanistic studies, including resistance selection with the most active compound (2) demonstrated that it acts as an inhibitor of the low pH-induced HA-mediated membrane fusion process. Computational studies identified an as yet unrecognized fusion inhibitor binding site, which is located at the bottom of the HA2 stem in close proximity to the fusion peptide. A direct p-stacking interaction between the N-benzylpiperidine moiety of 2 and F9HA2 of the fusion peptide, reinforced with an addi- tional p-stacking interaction with Y119HA2, and a salt bridge of the protonated piperidine nitrogen with E120HA2, were identified as important interactions to mediate ligand binding. This site rationalized the observed SAR and provided a structural explanation for the H1N1-specific activity of our inhibitors. Furthermore, the HA1-S326V mutation resulting in resistance to 2 is close to the proposed new binding pocket. Our findings point to the N-benzyl-4,4,-disubstituted piperidines as an interesting class of influenza virus inhibitors, representing the first example of fusion peptide binders with great potential for anti-influenza drug development

Evaluation of the Antiviral Effect of Polyglycerols Functionalized with Sialic Acid on Influenza Virus

Ein vielversprechender Ansatz zur Verhinderung von Infektionen mit Influenzavirus ist die kompetitive Inhibition der Virusanhaftung an die Wirtszellen durch Behinderung der Bindung des viralen Hemagglutinin (HA) an sialylierte Glykanrezeptoren. Allerdings erschwert die hohe Variabilität des HA die Entwicklung von universellen Sialinsäure (SA)-basierten Virostatika. In dieser Arbeit wurde der antivirale Effekt von mit SA funktionalisierten Polyglycerolen (PGs) auf Influenza A Viren (IAV) evaluiert. SA-basierte PGs waren nur bei der Inhibition einer geringen Anzahl an IAV Stämmen effektiv. Um die molekulare Basis für diese Beschränkung zu ergründen, wurden mittels Serienpassagen IAV Mutanten selektiert, die gegen sialyliertes PG resistent waren. Es entwickelten sich drei unabhängige resistente Virusvarianten, die einen einfachen bzw. doppelten Aminosäuren-Austausch in der HA RBS aufwiesen. Durch Hemagglutinations-Elution, Einzel-Virus Kraft-Untersuchungen und Glykanarray Analysen konnte eine verringerte Rezeptorbindungsstabilität sowie ein verändertes Rezeptorbindeprofil für diese Virusvarianten gezeigt werden. Interessanterweise wurden drei unterschiedliche Fälle von Virusbindung und Inhibition beobachtet: 1) Virales HA wurde vom PG gebunden und die Virusreplikation inhibiert, 2) virales HA wurde vom PG gebunden ohne Inhibition der Virusreplikation und 3) Virales HA wurde nicht vom PG gebunden und es gab keine Inhibition. Diese Ergebnisse suggerieren, dass es eine Mindestanforderung an die Affinität oder Avidität für eine effektive kompetitive Inhibition von HA gibt. Durch modifizierte PGs, die Sialyllaktose statt SA und einen Amidlinker enthielten, konnte das Potential von PGs als breite IAV Inhibitoren demonstriert werden. Zusammenfassend bieten die Ergebnisse dieser Arbeit wertvolle Einblicke in die Entwicklung von Resistenzen in IAV gegen Inhibitoren des HA-Attachment und in das strategische Design von sialylierten mutlivalenten Inhibitoren gegen IAV.A promising approach to block influenza virus infections is competitive inhibition of virus attachment to host cells by interfering with binding of the viral surface protein hemagglutinin (HA) to sialylated glycan receptors. However, the high structural and genetic variability of the viral HA has hampered the development of universal sialic acid (SA)-based antivirals. Here, the antiviral effect of biocompatible Polyglycerols (PGs) functionalized with SA on influenza A virus (IAV) was evaluated. PG compounds were only effective at inhibiting a narrow spectrum of IAV strains. To elucidate the molecular basis for this restriction, PG-resistant IAV mutants were selected using serial passaging. Three independent resistant variants developed with single or double amino acid changes mapping to the HA RBS. By employing hemagglutination elution, single-virus force measurements and glycan array analyses, a reduced receptor binding stability as well as an altered receptor binding profile of mutant viruses was shown. Intriguingly, three different cases of virus binding and inhibition were observed using Cy3-labeled compound: 1) viral HA was bound by the compound and resulted in inhibition of replication, 2) viral HA was bound by the compound but replication was not inhibited and 3) viral HA was not bound by the compound and no inhibition occurred. These results suggest that there is an affinity or avidity requirement for effective competitive inhibition of HA attachment. The suitability of PGs as IAV inhibitors with potential for broad activity was demonstrated by a modified PG incorporating sialyllactose instead of SA and an amide linkage covering an extended spectrum of inhibited IAV strains. Taken together, results described in this thesis provide valuable insights into the development of resistance against inhibitors of HA attachment in IAV and into the strategic design of sialylated, multivalent inhibitors aiming at broad activity against influenza viruses

Natural products against acute respiratory infections: Strategies and lessons learned

Under embargo until: 11.10.2020Ethnopharmacological relevance: A wide variety of traditional herbal remedies have been used throughout history for the treatment of symptoms related to acute respiratory infections (ARIs). Aim of the review: The present work provides a timely overview of natural products affecting the most common pathogens involved in ARIs, in particular influenza viruses and rhinoviruses as well as bacteria involved in co-infections, their molecular targets, their role in drug discovery, and the current portfolio of available naturally derived anti-ARI drugs. Materials and methods: Literature of the last ten years was evaluated for natural products active against influenza viruses and rhinoviruses. The collected bioactive agents were further investigated for reported activities against ARI-relevant bacteria, and analysed for the chemical space they cover in relation to currently known natural products and approved drugs. Results: An overview of (i) natural compounds active in target-based and/or phenotypic assays relevant to ARIs, (ii) extracts, and (iii) in vivo data are provided, offering not only a starting point for further in-depth phytochemical and antimicrobial studies, but also revealing insights into the most relevant anti-ARI scaffolds and compound classes. Investigations of the chemical space of bioactive natural products based on principal component analysis show that many of these compounds are drug-like. However, some bioactive natural products are substantially larger and have more polar groups than most approved drugs. A workflow with various strategies for the discovery of novel antiviral agents is suggested, thereby evaluating the merit of in silico techniques, the use of complementary assays, and the relevance of ethnopharmacological knowledge on the exploration of the therapeutic potential of natural products. Conclusions: The longstanding ethnopharmacological tradition of natural remedies against ARIs highlights their therapeutic impact and remains a highly valuable selection criterion for natural materials to be investigated in the search for novel anti-ARI acting concepts. We observe a tendency towards assaying for broad-spectrum antivirals and antibacterials mainly discovered in interdisciplinary academic settings, and ascertain a clear demand for more translational studies to strengthen efforts for the development of effective and safe therapeutic agents for patients suffering from ARIs.acceptedVersio

Synthesis and biological evaluation of nitrogen heterocycle systems as potential antiviral agents

Viruses are obligate intracellular parasites that consist of either double- or single-stranded DNA or RNA enclosed in a protein coat called capsid. Some viruses also possess a lipid envelope that, like the capsid, may contain antigenic glycoproteins. Most of them contain or encode enzymes essential for their replicative cycle inside host cells, sometimes usurping their metabolic machinery. Traditional therapeutic approaches have mostly focused on targeting specific viral components or enzymes. This pathogen-directed strategy, while successful in numerous cases, in many others results ineffective due to the emergence of drug-resistance. A different approach, addressed to target host-factors essential for viral replication, has recently draw an increasing attention. My PhD project aimed at synthesizing new nitrogen heterocycle systems, designed especially against RNA viruses, such as those belonging to Flaviviridae, Orthomyxoviridae and Paramyxoviridae families. Among them there are, respectively, pathogens responsible for diseases with a high epidemiological impact, as BVDV in cattle and HCV in humans, influenza A and B viruses and respiratory syncytial virus (RSV). The project has been organized into the following phases: 1. Chemical synthesis of the novel compound series. During my PhD I designed and synthesized diverse chemical series of different chemotypes, in order to obtain new antiviral agents: the acridine nucleus, the dihydrotriazine scaffold, the benzimidazole ring as well as anilino and benzenesulfonamide derivatives. Previous studies performed by the research group where I develop my Ph.D. thesis identified some prototypes for the different classes endowed with intrinsic antiviral activity; thus, during my Ph.D. research work I explored various possibilities of functionalisation with the aim of increasing their potency and selectivity profiles towards the respective antiviral target. 2. Characterization of the new compounds. Each newly synthesized compound have been characterised by spectroscopic methods (such as UV, IR, 1H-NMR and 13C-NMR) and elemental analysis. 3. Evaluation of cytotoxicity, antiviral activity in vitro, enzymatic assays and computational studies have been performed in collaboration with several national and international research groups, to assess the biological activity and to identify/confirm the respective molecular targets